Skip to main content

Table 1 Susceptibility of lower respiratory tract infection isolates of P. aeruginosa and Enterobacterales to C/T and comparator agentsa,b – SMART 2018–2019, United States

From: Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Species n % Susceptible
C/T P/T FEP CAZ CRO ATM MEM IMI LVX AMK
P. aeruginosa 1237 96.0 74.4 79.2 78.5 NA 68.2 74.8 65.2 63.1 96.0
All Enterobacteralesc 1938 91.8 88.0 89.5 83.4 80.1 84.2 98.0 86.4 82.2 98.8
K. pneumoniae 432 92.6 86.8 82.2 79.9 80.3 81.9 96.5 95.1 81.0 98.4
E. coli 359 97.2 91.9 84.7 82.2 79.4 82.5 99.7 99.7 66.6 98.9
S. marcescens 261 95.8 93.5 96.6 95.8 84.3 93.5 96.9 84.3 90.8 97.3
E. cloacae 176 77.8 79.0 89.8 72.2 69.3 73.9 98.9 94.3 94.3 100
K. aerogenes 152 79.6 73.0 94.1 70.4 67.8 72.4 98.0 73.0 93.4 100
K. oxytoca 138 97.8 87.7 94.9 96.4 87.0 91.3 97.8 97.1 99.3 100
P. mirabilis 121 99.2 100 95.0 96.7 95.9 97.5 100 19.8 61.2 99.2
P. aeruginosa + Enterobacterales 3175 93.5 82.7 85.5 81.5 NA 78.0 88.9 78.2 74.8 97.7
  1. a Abbreviations: C/T, ceftolozane/tazobactam; P/T, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ATM, aztreonam; MEM, meropenem; IMI, impenem; LVX, levofloxacin; AMK, amikacin, NA, not available
  2. b Table does not show results for colistin because P. aeruginosa and Enterobacterales cannot be categorized as susceptible to colistin using CLSI M100 (2020) MIC breakpoint criteria
  3. c Table only shows data for individual species of Enterobacterales when n > 100